Precision Medicine in Oncology®

Joshua K. Sabari, MD, shares how the unique pharmacokinetics and mechanism of action for LY3537982 supported its investigation in the LOXO-RAS- 20001 study, findings presented at AACR, and how this research could address unmet needs in patients with KRAS G12C–mutant solid tumors.

A genome-wide methylome enrichment platform demonstrated efficacy in detecting early-stage, low-shedding cancers with limited circulating tumor DNA.

Shannon N. Westin, MD, MPH, FACOG, shares preclinical data that provided the impetus for the SOLAR trial of olaparib and selumetinib in patients with RAS-mutated gynecologic cancers, key findings from the dose-escalation and -expansion portions of the research, and next steps with the combination.

In the setting of cancer, cytokines contribute to cells’ antitumor response, cell damage, inflammation, angiogenesis, metastasis, and other cellular processes that enable tumor survival

Andre Goy, MD, discusses advances in the field of oncology that prompted the development of the Hennessy Institute, how early cancer detection can improve patient outcomes, and the importance of employing accessible cancer prevention strategies.

The evaluation of diagnostic quality in precision medicine should almost certainly be assessed by standards different from those used in drug development.

Siamak Daneshmand, MD, shed light on the phase 2 THOR-2 study evaluating different cohorts of patients with recurrent NMIBC, key findings from cohorts 2 and 3, and how ongoing research seeks to move the needle forward with novel drug delivery methods.

Brian Henick, MD, discusses the importance of further exploring biomarkers in the immune microenvironment for immunotherapy in patients with lung cancer.

The FDA has approved dabrafenib with trametinib for the treatment of pediatric patients 1 year of age and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy.

In this sixth episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses the consideration of adverse effects related to treatment with TKIs patients in non–small cell lung cancer.

Vorasidenib monotherapy elicited a statistically significant and clinically meaningful improvement in progression-free survival compared with placebo in patients with residual or recurrent IDH1/2-mutant low-grade glioma.

Adjuvant osimertinib and other targeted therapies, such as KRAS G12C inhibitors, could continue to change the perioperative treatment landscape in non–small cell lung cancer.

The FDA has placed a clinical hold on a phase 1 trial investigating the antibody-drug conjugate XMT-2056 for the treatment of patients with advanced/recurrent solid tumors that express HER2.

Closing out their discussion on biomarkers and precision medicine in cancer care, key opinion leaders look toward future evolutions in the oncology landscape.

Ryan Haumschild, PharmD, MS, MBA, reflects on how oncologic pharmacists can help to develop treatment pathways and educate patients on precision medicine.

Patients with metastatic castration-resistant prostate cancer have traditionally been burdened by a poor outlook; however, emerging therapeutic targets and novel agents directed at them are poised to affect change in this population.

Precision medicine has arrived in all stages of prostate cancer care and recommendations for optimal testing and how best to leverage the results to inform clinical decisions continue to rapidly evolve.

Lisa M. Carey, MD, ScM, FASCO, discusses upcoming treatments that could impact standard-of-care practices and the continually evolving role of antibody-drug conjugates role in the breast cancer treatment paradigm.

Susan M. Domchek, MD, highlights key points related to her presentation on germline testing and breast cancer treatment.

An understanding of BET protein dysregulation, which leads to abnormal expression of oncogenes, has prompted investigators to explore the idea of these proteins as a therapeutic target for cancer.

Eleni Efstathiou, MD, PhD, expands on the updated interim data from the MAGNITUDE trial and sheds light on the utility of PARP inhibitor combinatorial strategies in patients with mCRPC and HRR gene alterations.

The FDA has approved the VENTANA PD-L1 assay for expanded use in patients with advanced non–small cell lung cancer to help identify patients who may be candidates for treatment with cemiplimab.

Lasofoxifene improved vaginal/vulvar symptoms compared with fulvestrant in premenopausal patients with locally advanced or metastatic estrogen receptor–positive/HER2-negative breast cancer harboring an ESR1 mutation.

The antibody-drug conjugate trastuzumab deruxtecan met the prespecified target for objective response rate and demonstrated durable responses in heavily pretreated patients with HER2-expressing advanced solid tumors in the phase 2 DESTINY-PanTumor02 trial.

Expert perspectives on the role of an oncologic pharmacist within a tumor board and how they can improve upon precision medicine in cancer management.

Comprehensive discussion on the role of tumor boards—or more specifically, molecular tumor boards—in the optimal management of patients with cancer.

Neville E. Sanjana, PhD, discusses a study on the predictive utility of the Cancer Immunotherapy Response CLassifiEr in advanced-stage cancers.

Key opinion leaders in the field of cancer management discuss resistance to the uptake of biomarker testing and precision medicine, with deference to the community setting.

Expert pathologist Samuel K. Caughron, MD, FCAP, shares best strategies for the timing and utilization of biomarker testing while managing patients with cancer.